Drug intelligence / Profile preview

GPCRs PAC

Development stage: Preclinical
Lead developer: Peptilogics
Modality: Peptides

Overview

GPCRs PAC is a preclinical-stage drug candidate developed by Peptide Logic for the treatment of inflammatory conditions. It is designed as a peptide-based agonist targeting G protein-coupled receptors (GPCRs). Peptide Logic's platform focuses on engineering peptides with improved pharmacological properties, such as peripheral restriction or enhanced selectivity, to modulate cell-surface receptors. While the specific GPCR target for this program has not been publicly disclosed, the candidate is intended to leverage GPCR signaling pathways to achieve anti-inflammatory effects.

Beyond the preview

Go deeper on GPCRs PAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GPCRs PAC.

Explore the full profile